The process leads to standardized psychedelic extracts that are reproducible, scalable, cost effective, and commercially viable
VANCOUVER, BC, June 24, 2021 / CNW / – Numinus Well-being Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company that provides innovative treatments and evidence-based psychedelic-assisted therapy, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that significantly increases the production of therapeutics for use in assisted psychotherapy. psychedelic.
The sustainable, reproducible and easily scalable process will be used to rapidly generate therapeutic products from psychoactive mushroom species containing psilocybin, other psychoactive compounds and a range of additional beneficial compounds, which some researchers at Numinus have characterized for the first time in psychedelic mushrooms. The resulting psychedelics are intended to be delivered in micro or macro doses to help treat mental health disorders that affect millions of people around the world.
“At Numinus, one of the main goals of our lab’s research and discovery work is to support accessibility to psychedelic-assisted psychotherapy,” said Sharan sidhu, Managing Director and Scientific Director of Numinus Bioscience. “The rapid production process announced today achieves this goal by improving our ability to transparently formulate safe and effective products with consistent psychoactive properties at scale, with the regulatory confidence that comes with standardized products. ”
Numinus first tested the production process to quickly generate a Psilocybe extract of species as “proof of concept”. The results revealed a highly efficient and evolutionary process that can be applied to other species of psychoactive fungi. Numinus will assess the clinical efficacy and safety of an extract generated using its proprietary technology in an upcoming Phase 1 clinical trial, which was announced in April 2021. The Company’s goal is to develop proprietary technology to make psychedelic products generated from psychoactive mushrooms more readily available in a market which may become regulated in the future.
“As research interest and the demand for compassionate access to psychedelics increase, patients will need safe therapeutics that offer consistent psychoactive properties and are scalable,” said Payton Nyquvest, CEO, Numinus. “With this in mind, we believe the rapid production process has the potential to transform the industry and ensure that as many people as possible have the opportunity to benefit from mental health treatments and promote their well-being. “
Today’s announcement reinforces the leadership of the Numinus Bioscience laboratory in the development of new psychedelic therapies, and highlights the opportunities resulting from the intellectual property strategy pursued by Numinus. This includes basic research into discoveries and laboratory processes that are reproducible, sustainable, profitable and patentable.
Below from Canada Controlled Drugs and Substances Act, Numinus Bioscience can own, produce, assemble, sell, export and ship a wide variety of psychedelics, including ketamine, lysergic acid diethylamide (LSD), mescaline, N, N-dimethyltryptamine (DMT), N-methyl-3,4, methylenedioxyamphetamine (MDMA), psilocin and psilocybin.
Numinus Wellness (TSX-V: NUMI) helps people heal and feel good through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic therapies. The Numinus Wellness model – including psychedelic production, research and clinical care – is at the forefront of a transformation to heal rather than manage symptoms of depression, anxiety, trauma , pain and addiction. At Numinus, we lead the integration of psychedelic-assisted therapy into mainstream clinical practice and lay the foundation for a healthier society.
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, goals, assumptions, expectations or beliefs regarding future performance, are “forward-looking statements”. Forward-looking statements may be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimated”, “is considering”, “anticipates” or “Does not anticipate”, or “believe” or variations of these words and phrases or statements that certain actions, events or results “could”, “could”, “could”, “could” or “would” be taken, occur or be carried out. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to differ materially from the future results, events or developments expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, reliance on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses and any inability to obtain all government approvals, licenses and permits necessary to operate and expand the Company’s business facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization of psychedelic therapies, due to inconsistent public opinion, perceived medical use of psychedelics, delays or inefficiencies or for any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating history and the lack of historical earnings; dependence on management; the Company’s needs for additional financing and the effect of capital market conditions and other factors on the availability of capital; competition, including from more established or better funded competitors; the need to establish and maintain alliances and corporate partnerships, including with research and development institutions, customers and suppliers; the development and implementation of medical protocols and treatment standard operating procedures for the use of psychedelic therapies; the Company’s goals of developing and implementing partnerships with research organizations and other key players in the integrative mental health industry; the Company’s ability to successfully resist the economic impact of COVID-19; the medical benefits, safety, efficacy, dosage, and social acceptance of psychedelics; the approval and / or success of compassionate access clinical trials; growing and harvesting Psilocybe mushrooms; and the availability of qualified personnel and health professionals. These factors should be carefully considered, and readers are cautioned not to place undue reliance on these forward-looking statements. Although the Company has attempted to identify material risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actual actions to differ. actions, events or results differ from those anticipated, estimated or predicted. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in the forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Numinus Bien-être Inc.
For further information: May Lee, Communications Manager, Numinus, [email protected]; For media inquiries: Catherine Snider, Kaiser & Partners, [email protected]